Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

FDA Approves Generic Abortion Pill Amid Political Backlash, While Biotech Companies Report Promising Drug Development Progress

The pharmaceutical industry saw significant developments this week, with regulatory decisions sparking controversy and biotech firms making strides in drug development. Here's a comprehensive look at the latest news:The U.S. Food and Drug Administration (FDA) has approved a second generic version of mifepristone, a key component in medication abortions. Privately held Evita Solutions received clearance for their formulation of the drug, which is commonly used to terminate pregnancies within the first trimester.

NoahAI News10/4/2025

Pharmaceutical Industry Faces Ongoing Layoffs Amid Shifting Priorities

The pharmaceutical industry continues to grapple with widespread layoffs and strategic restructuring as companies navigate a challenging landscape marked by financial pressures and evolving research priorities. Recent developments highlight a trend of workforce reductions across major pharmaceutical firms and biotech companies, with implications for various therapeutic areas and research modalities.

NoahAI News10/4/2025

Takeda Exits Cell Therapy Arena in Strategic Shift, Reshaping Industry Landscape

Takeda Pharmaceutical Company, the Japanese multinational, has announced a significant strategic pivot, exiting the cell therapy field and realigning its focus on three core modalities. This move, part of a broader restructuring effort, marks a notable shift in the pharmaceutical landscape and underscores the challenges faced by cell therapy development.

NoahAI News10/2/2025

Job Security in Biopharma: High-Growth Areas and Development Roles Take Center Stage

As layoffs continue to ripple through the biopharmaceutical industry, professionals are increasingly seeking ways to safeguard their careers. Recent insights from talent acquisition experts suggest that focusing on high-growth areas and development roles may offer the best job security in these uncertain times.

NoahAI News10/2/2025

AI-Driven Drug Discovery Platform Nanyang Biologics Set for Nasdaq Debut via SPAC Merger

Nanyang Biologics (NYB), a Singapore-based artificial intelligence-driven drug discovery platform, is poised to make its entrance on the Nasdaq through a reverse merger with RF Acquisition Corp II (RFA), a special purpose acquisition company. The deal, announced on October 2, 2025, values NYB at $1.5 billion and is expected to close by the second quarter of 2026.

NoahAI News10/2/2025

Roche Secures 89bio Acquisition in $3.5 Billion Deal, Expanding MASH Pipeline

Roche has successfully acquired 89bio in a deal worth up to $3.5 billion, marking a significant expansion of its metabolic dysfunction-associated steatohepatitis (MASH) pipeline. The acquisition comes after an extensive courtship process involving multiple pharmaceutical companies and months of negotiations.

NoahAI News10/2/2025

Ansa Biotechnologies Secures $54.4M in Series B Funding to Accelerate DNA Synthesis Platform

Ansa Biotechnologies, a San Francisco-based biotech company specializing in DNA synthesis, has successfully closed an oversubscribed series B financing round, raising a total of $54.4 million. The funding, led by Cerberus Ventures, will be used to expand the company's DNA synthesis production capacity in the United States.

NoahAI News10/2/2025

Cartography Biosciences Secures $67M in Series B Funding for Novel Cancer Therapies

Cartography Biosciences, a San Francisco Bay Area biotechnology company, has announced a successful $67 million Series B funding round to advance its innovative cancer treatment pipeline. The company's lead program, CBI-1214, is poised to enter clinical trials early next year, targeting colorectal cancer with a novel T cell engager approach.

NoahAI News10/2/2025

Bolt Biotherapeutics Cuts Workforce Again, Delays Key Immunotherapy Readout

Bolt Biotherapeutics, a clinical-stage oncology company, has announced a significant workforce reduction and a delay in the readout of its lead immunotherapy candidate. This move comes as the biotech navigates challenging market conditions and seeks to extend its cash runway.

NoahAI News10/2/2025

Takeda Abandons Cell Therapy Research in Strategic Shift

Japanese pharmaceutical giant Takeda has announced a significant change in its research and development strategy, deciding to exit the field of cell therapy research. This move marks a notable reversal for the company, which had previously identified cell therapy as a key priority in its pipeline.

NoahAI News10/2/2025

FDA Rejects Fortress and Sentynl's Treatment for Rare Pediatric Disease, Citing Manufacturing Issues

The U.S. Food and Drug Administration (FDA) has rejected the investigational treatment for Menkes disease developed by Fortress Biotech and Sentynl Therapeutics. The decision, announced on Wednesday, marks another setback in the rare disease space, where manufacturing issues continue to challenge drug approvals.

NoahAI News10/2/2025

AnaptysBio Announces Strategic Split into Biopharma and Royalty Management Companies

AnaptysBio, a San Diego-based biopharmaceutical company, has unveiled plans to separate its business into two distinct publicly traded entities by the end of 2026. This strategic move aims to sharpen investor focus on the company's diverse asset portfolio and potentially unlock greater value for shareholders.

NoahAI News10/2/2025

«1...37 38 39...67 »